The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
DNA Mismatch Repair
Drug Resistance, Neoplasm
Epstein-Barr Virus Infections
/ drug therapy
Female
Follow-Up Studies
Gastric Mucosa
/ pathology
Herpesvirus 4, Human
/ isolation & purification
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Male
Middle Aged
Progression-Free Survival
Receptor, ErbB-2
/ analysis
Retrospective Studies
Stomach Neoplasms
/ drug therapy
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 07 2020
15 07 2020
Historique:
received:
08
01
2020
revised:
19
02
2020
accepted:
05
03
2020
pubmed:
12
3
2020
medline:
3
11
2021
entrez:
12
3
2020
Statut:
ppublish
Résumé
We evaluated the association between molecular subtypes of advanced gastric cancer (AGC) and the efficacy of standard chemotherapy or immune checkpoint inhibitors. Patients with AGC who received systemic chemotherapy from October 2015 to July 2018 with available molecular features were analyzed. We investigated the efficacy of standard first- (fluoropyrimidine + platinum ± trastuzumab) and second-line (taxanes ± ramucirumab) chemotherapy, and subsequent anti-PD-1 therapy in patients with four molecular subtypes: MMR-D (mismatch repair deficient), EBV 410 patients were analyzed: MMR-D 5.9%, EBV MMR-D might result in shorter PFS with first-line chemotherapy for AGC. Subsequent anti-PD-1 therapy achieved higher ORR and longer PFS than prior chemotherapy in most patients with MMR-D, supporting the earlier use of immune checkpoint inhibitors.
Identifiants
pubmed: 32156744
pii: 1078-0432.CCR-20-0075
doi: 10.1158/1078-0432.CCR-20-0075
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3784-3790Informations de copyright
©2020 American Association for Cancer Research.